Newsletter March 2021
The upcoming subscription period for TO 1 B
Tuesday is the first day to exercise Cline Scientific warrant CLINE TO 1 B for the subscription of the new share emissions. One warrant entitles the holder to subscribe for one new share at the price of 3.38 SEK per share in the period of 2 – 12 March 2021. CLINE TO 1 B warrants can be traded until 10 March 2021.
Upon full exercise of the Warrants, approximately SEK 13.5 million will be provided to Cline. The issue costs are estimated at approximately SEK 100 thousand.
Full terms of the warrant and the application form with instructions for payment will be available on the Company's website www.clinescientific.com and Aktieinvest FK AB's website https://www.aktieinvest.se/.
Kicking off V.A. Cure collaboration
February saw the start of our latest collaboration that we communicated in the February newsletter. Our labs at the BioVentureHub are buzzing with activity as the team has been preparing gradient surfaces and beginning the work to help address the great need to uncover the underlying biology of vascular disease. Vascular anomalies are a type of vascular diseases, where there is abnormal development of vessels, either blood, lymphatic or both, which range from mild to life-threatening. There is an estimated prevalence of 4.5%, often diagnosed in at birth or at an early age. In most cases there is not a cure and some patients need life-long clinical management. Treatment success is often partial, leaving patients with chronic pain, dysfunction and lowered quality of life.
Stay tuned for more updates in our newsletter.
StemCART
The patent application which was submitted to the European patent Office (EPO) at the beginning of 2020 will soon be followed by an international patent application, (PCT). This is the next stage in the strategy for the StemCART project and will serve as a strong protection of the unique process of therapy development based on Cline’s gradient technology.
After being granted SME designation by EMA (European Medicines Agency), which is the first step in certifying Clines method for the production of ATMPs (Advanced therapy medicinal products), we will during the rest of 2021 prepare this project for the initiation of a phase 1 clinical study. Projected start of this is currently during 2022.
CellRACE
Our diagnostic project, CellRACE, has started up the testing of the prototype on fresh patient biopsies after a period of unavailability of biopsy material due to the pandemic. We look forward to completing these tests during the first half of this year as it was planned during 2020. During this time, we will also prepare an application for Ethical Permit which is a requirement in order to initiate our first patient study. Preparations and patient recruitment for this are planned for the fall, and the study still planned to commence during 2021.
Plans for a technical patent which could protect one or several key aspects of the CellRACE method is currently being looked into, and we expect to communicate this within the coming few months.
Interest and investment in the IVD and cancer diagnostic market continue to grow. According to a 2020 market report, the global in-vitro diagnostic market has grown to $83 Billion USD. Tissue-based and molecular testing for cancer is a key driver in this growth, with the growth rate being 50% higher than the average across the sector. The importance of earlier and more precise diagnostics is being increasingly recognised across healthcare.
In February, advanced genomic diagnostic company Veracyte expanded their cancer testing portfolio through the acquisition of Decipher Biosciences, leaders in urologic cancers, for $600 M USD.
Similarly, US-based Oncocyte, who recently launched DetermaRx™, a test that identifies early lung cancer patient at risk of recurrence, acquired German Chronix Biomedical. Chronix use cell-free DNA changes to monitor treatment progress during immunotherapy treatment.
We will continue to keep you updated, keep an eye on the website and other communication channels to follow the development. Feel free to contact us if you have questions or suggestions and do not forget to subscribe to our newsletter!
Warmest regards,
The Cline Team
Click here subscribe to future newsletters and press releases. https://news.cision.com/cline/SubscriptionRegistrationDialog
Cline Scientific AB (publ) Phone: 031-387 55 55
Argongatan 2 C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase